Varenicline shows promise, but cannabis treatment evidence remains mixed
Varenicline for the management of cannabis use disorder: A systematic review.
AI Summary
Cannabis use disorder (CUD) is common, while existing psychosocial treatments provide only modest benefits and no medication is currently approved specifically for CUD. This systematic review examined varenicline, a nicotinic-receptor partial agonist approved for smoking cessation, as a possible treatment for cannabis use and withdrawal. The review included 5 studies involving 299 participants: 4 randomized controlled trials and one case series. Because the studies used methods that were too different, the authors conducted a narrative rather than statistical synthesis.
Results were mixed. The one study judged to be good quality found significant reductions in cannabis use and withdrawal symptoms, but the review concluded that the overall evidence remains insufficient for confident conclusions in adolescents or adults. Tolerability and effects on concurrent tobacco use were also inconsistent. In the higher-quality study, overall adverse-event rates did not differ between varenicline and placebo, although nausea was more common with varenicline. More research is needed before it can be considered a reliable treatment option for CUD.
π‘ Key Findings
π
Original Abstract
Related Research
Similar Studies
More Addiction research papers you might find interesting.
Treatment records show a sharp rise in stimulant use in Oman, 2019β2024
An 18-month cohort found adverse outcomes were infrequent, but long-term risksβ¦
Barcelona survey links teen pornography use with cannabis use and other outcomes
Explore More Research
Stay informed about the latest cannabis science.